Flovent Powder, Metered
Product Images NDC 63187-957

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Flovent (NDC 63187-957). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Flovent Diskus Spl Graphic 01)

Chemical structure of fluticasone propionate, showing its complex steroid backbone with fluorine and other functional groups.*

FDA Label Image

Figure 1. A 12-week Clinical Trial Evaluating Flovent Diskus 100 Mcg Twice Daily In Adults And Adolescents Receiving Bronchodilators Alone (Flovent Diskus Spl Graphic 02)

Line graph showing the percent change from baseline in FEV1 over 12 weeks comparing FLOVENT DISKUS 100 mcg twice daily with placebo. The x-axis represents weeks, and the y-axis shows percent change in baseline FEV1. FLOVENT DISKUS demonstrates a greater and sustained increase compared to placebo throughout the study period.*

FDA Label Image

Figure 2. A 12-week Clinical Trial Evaluating Flovent Diskus 100 Mcg Twice Daily In Adults And Adolescents Receiving Inhaled Corticosteroids (Flovent Diskus Spl Graphic 03)

A line graph comparing the percentage change from baseline in FEV1 over 12 weeks between FLOVENT DISKUS 100 mcg twice daily and placebo. The x-axis represents weeks 0 to 12 and the endpoint, while the y-axis shows percentage change from baseline in FEV1. FLOVENT DISKUS shows a greater positive change over time compared to placebo.*

FDA Label Image

Figure 3. A 12-week Clinical Trial Evaluating Flovent Diskus 250 Mcg Twice Daily In Adults And Adolescents Receiving Inhaled Corticosteroids Or Bronchodilators Alone (Flovent Diskus Spl Graphic 04)

A line graph comparing the percentage change from baseline in FEV1 over 12 weeks between FLOVENT DISKUS 250 mcg twice daily and placebo groups. The x-axis shows weeks from 0 to 12 plus an endpoint, and the y-axis shows percentage change from baseline in FEV1, ranging from -10% to 25%. FLOVENT DISKUS group shows a marked increase peaking near 20%, while placebo remains near zero or below throughout.*

FDA Label Image

Figure 4. A 12-week Clinical Trial Evaluating Flovent Diskus 500 Mcg Twice Daily In Adults And Adolescents Receiving Inhaled Corticosteroids Or Bronchodilators Alone (Flovent Diskus Spl Graphic 05)

A line graph depicting percentage change from baseline in FEV1 over a 12-week period comparing FLOVENT DISKUS 500 mcg twice daily versus placebo. The x-axis represents weeks 0 to 12 and the endpoint, while the y-axis shows percentage change. FLOVENT DISKUS data is marked by squares and shows higher increases compared to placebo, which is marked by diamonds.*

FDA Label Image

Figure A (Flovent Diskus Spl Graphic 06)

Illustration of the Flovent Diskus inhaler, labeled with its main parts: outer case, mouthpiece, lever, thumb grip, and counter. The label on the device indicates it contains Flovent Diskus with fluticasone propionate inhalation powder, 100 mcg, and holds 60 blisters.*

FDA Label Image

Figure B (Flovent Diskus Spl Graphic 07)

An instructional illustration shows hands holding a FLOVENT DISKUS inhaler. An arrow indicates the direction to slide the lever on the device to prepare a dose for inhalation.*

FDA Label Image

Figure C (Flovent Diskus Spl Graphic 08)

An instructional image showing hands holding a FLOVENT DISKUS inhaler. A white arrow indicates the direction to rotate the device, demonstrating how to prepare a dose for inhalation.*

FDA Label Image

Figure D (Flovent Diskus Spl Graphic 09)

An instructional illustration showing a woman demonstrating proper use of the FLOVENT DISKUS inhaler device. She holds the device near her mouth, preparing to inhale the powder medication, emphasizing correct inhalation technique for respiratory delivery.*

FDA Label Image

Figure E (Flovent Diskus Spl Graphic 10)

An instructional illustration showing a woman using a FLOVENT DISKUS inhaler, demonstrating the respiratory inhalation administration of fluticasone propionate powder.*

FDA Label Image

Figure F (Flovent Diskus Spl Graphic 11)

Instructional illustration showing hands operating a FLOVENT DISKUS inhaler by sliding the lever to prepare the dose for inhalation. The device delivers fluticasone propionate powder, 100 micrograms per actuation, for respiratory use.*

FDA Label Image

Figure G (Flovent Diskus Spl Graphic 12)

An illustration showing a woman looking at a glass of water positioned next to a sink faucet. This appears to be an instructional or contextual figure potentially related to medication usage or preparation.*

FDA Label Image

Figure H (Flovent Diskus Spl Graphic 13)

Packaging of FLOVENT DISKUS inhalation powder 100 mcg, a metered powder for respiratory inhalation containing fluticasone propionate. The device label shows it contains 60 blisters (doses) and has markings for punch opened and use by dates. The product is labeled by Proficient Rx LP.*

FDA Label Image

63187-957-60 (Flovent Diskus Spl Graphic 15)

Flovent Diskus 100 mcg inhaler label for 60 doses. Contains 100 mcg of fluticasone propionate with lactose per blister. For oral inhalation only. Manufactured by GlaxoSmithKline, made in Singapore. Storage recommended between 68°F and 77°F. Relabeled by Proficient Rx LP, Thousand Oaks, CA. Includes NDC 63187-957-60 and product ID RF095760.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.